In refractory/relapsed multiple myeloma(RRMM),chimeric antigen receptor-T(CAR-T)cell therapy represents a significant scientific advancement,with high response rates and long-term remission for many patients.However,target antigen downregulation on tumor cells can lead to poor response and disease recurrence.Currently,CAR-T cell therapy approved for the treatment of RRMM only targets B cell maturation antigen(BC-MA).Although BCMA-CAR-T cell therapy has a high response rate,its selective pressure on target antigens can cause BCMA loss and MM escape.Bispecific CAR-T cells theoretically have the advantages of broader targeting and less single-target escape.BCMA and CS1 are highly expressed on MM cells and are considered ideal targets for MM immunotherapy.This review summarizes the research progress of commercial BCMA-CAR-T cell therapy for RRMM and CS1-CAR-T cell therapy for MM and focuses on the primary results of CS1-BCMA CAR-T cells.
维普
万方数据